Ainslie L.K. Derrick‐Roberts

Author

Also Known As

Ainslie Derrick Roberts, Ainslie Derrick-Roberts, Ainslie L K Derrick-Roberts, Ainslie L K Roberts, Ainslie L. K. Derrick-Roberts, Ainslie L. K. Derrick‐Roberts, Ainslie L.K. Derrick Roberts, Ainslie L.K. Derrick-Roberts, Ainslie L.K. Derrick‐Roberts, Ainslie L.K. Roberts

Publications

582

Citations

H-Index

Concepts

All Affiliations

The University of Adelaide South Australia Pathology Women's and Children's Health Network Women's and Children's Hospital University of South Australia

About

Ainslie L.K. Derrick‐Roberts is an author at The University of Adelaide specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	398
2	Engineering	2	2	72
3	Public Health	1	1	16
4	Social Sciences	1	1	71
5	Biochemistry	1	1	10

Ainslie L.K. Derrick‐Roberts

Publications

536

Citations

H-Index

Page 1

	Year	Citations
Inhibition of Glycosaminoglycan Synthesis Using Rhodamine B in a Mouse Model of Mucopolysaccharidosis Type IIIA Ainslie L.K. Derrick‐Roberts, Belinda J. Thomas, Ashley Wilkinson, Pediatric Research Mucopolysaccharidosis Type IiiaMedicineGlycobiologyImmunologyPharmacology	2006	82
Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA Ainslie L.K. Derrick‐Roberts, Matthew Rees, Sonja Klebe, Molecular Genetics and Metabolism Knockout MouseMps IiiaBehavioral NeuroscienceMedicinePhysiology	2007	71
Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses Xenia Kaidonis, Wan Chin Liaw, Ainslie L.K. Derrick‐Roberts, European Journal of Human Genetics EngineeringMedicineBiotechnologyGenetic EngineeringMolecular Biology	2009	45
Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA Chantelle McIntyre, Ainslie L.K. Derrick‐Roberts, Enzo Ranieri, Molecular Genetics and Metabolism Gene TherapiesImmunologyAntiviral ResponseLentiviral-mediated Gene TherapyHiv	2008	38
Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Donald S. Anson, Chantelle McIntyre, Belinda J. Thomas, Genetic Vaccines and Therapy	2007	35
Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII Carmen E. Macsai, Ainslie L.K. Derrick‐Roberts, Xiaodan Ding, Molecular Genetics and Metabolism Regenerative MedicineMps ViiGene TherapiesBone Morphogenic ProteinSkeletal Response	2012	31
Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA Ainslie L.K. Derrick‐Roberts, Janice M. Fletcher, Lynette Moore, Molecular Genetics and Metabolism Rhodamine BTrans-generational ExposurePathogenesisImmunologyPathology	2010	28
Electrochemically Enhanced Antimicrobial Action of Plasma‐Activated Poly(Vinyl Alcohol) Hydrogel Dressings Sumyea Sabrin, Sung‐Ha Hong, Sushil Kumar KC, Advanced Functional Materials Biopolymer GelHydrogelsChemical EngineeringBiomanufacturingPva Hydrogel	2024	27
Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery Chantelle McIntyre, Ainslie L.K. Derrick‐Roberts, Sharon Byers, The Journal of Gene Medicine	2014	24
Lentiviral-Mediated Gene Therapy Results in Sustained Expression of β-Glucuronidase for up to 12 Months in the Gus <sup> <i>mps/mps</i> </sup> and up to 18 Months in the Gus <sup> <i>tm(L175F)Sly</i> </sup> Mouse Models of Mucopolysaccharidosis Type VII Ainslie L.K. Derrick‐Roberts, Carmen E. Pyragius, Xenia Kaidonis, Human Gene Therapy	2014	21

Page 1